Approval · Notice of Compliance 36863 · 2026
VIMIZIM: Notice of Compliance 36863
Issued February 6, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36863
- Date
- February 6, 2026
- Company
- Biomarin International LimitedRingaskiddy, Cork, Ireland
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of a manufacturing facility for the drug product
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VIMIZIM | Not yet assigned | — |
Medicinal ingredients
- ELOSULFASE ALFA 1 MG per ML